These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16424795)

  • 1. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension.
    Martinez ML; Lopes LF; Coelho EB; Nobre F; Rocha JB; Gerlach RF; Tanus-Santos JE
    J Cardiovasc Pharmacol; 2006 Jan; 47(1):117-22. PubMed ID: 16424795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats.
    Martinez ML; Castro MM; Rizzi E; Fernandes K; Demacq C; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Eur J Pharmacol; 2008 Sep; 591(1-3):224-30. PubMed ID: 18634778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats.
    Martinez ML; Rizzi E; Castro MM; Fernandes K; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Eur J Pharmacol; 2008 Dec; 599(1-3):110-6. PubMed ID: 18930722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.
    Derosa G; Mugellini A; Pesce RM; D'Angelo A; Maffioli P
    BMC Cardiovasc Disord; 2016 Apr; 16():66. PubMed ID: 27068332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment.
    Zervoudaki A; Economou E; Stefanadis C; Pitsavos C; Tsioufis K; Aggeli C; Vasiliadou K; Toutouza M; Toutouzas P
    J Hum Hypertens; 2003 Feb; 17(2):119-24. PubMed ID: 12574790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
    Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension.
    Marçal DM; Rizzi E; Martins-Oliveira A; Ceron CS; Guimaraes DA; Gerlach RF; Tanus-Santos JE
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):35-44. PubMed ID: 21058008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mercury exposure increases circulating net matrix metalloproteinase (MMP)-2 and MMP-9 activities.
    Jacob-Ferreira AL; Passos CJ; Jordão AA; Fillion M; Mergler D; Lemire M; Gerlach RF; Barbosa F; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2009 Oct; 105(4):281-8. PubMed ID: 19594729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension.
    Zervoudaki A; Economou E; Pitsavos C; Vasiliadou K; Aggeli C; Tsioufis K; Toutouza M; Stefanadis C; Toutouzas P
    Am J Hypertens; 2004 Mar; 17(3):273-6. PubMed ID: 15001203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.
    Li-Saw-Hee FL; Edmunds E; Blann AD; Beevers DG; Lip GY
    Int J Cardiol; 2000 Aug; 75(1):43-7. PubMed ID: 11054505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study.
    Rachmani R; Levi Z; Zadok BS; Ravid M
    Clin Pharmacol Ther; 2002 Sep; 72(3):302-7. PubMed ID: 12235451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 levels in children with primary hypertension.
    Niemirska A; Litwin M; Trojanek J; Gackowska L; Kubiszewska I; Wierzbicka A; Kułaga Z; Michałkiewicz J
    J Hypertens; 2016 Sep; 34(9):1815-22. PubMed ID: 27379542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exogenous l-arginine reduces matrix metalloproteinase-2 and -9 activities and oxidative stress in patients with hypertension.
    Garcia VP; Rocha HNM; Silva GM; Amaral TAG; Secher NH; Nóbrega ACL; Vianna LC; Rocha NG
    Life Sci; 2016 Jul; 157():125-130. PubMed ID: 27287681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lercanidipine on kidney microanatomy in Cohen-Rosenthal diabetic hypertensive rats.
    Rosenthal T; Rosenmann E; Tomassoni D; Amenta F
    J Cardiovasc Pharmacol Ther; 2007 Jun; 12(2):145-52. PubMed ID: 17562785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed-dose combination lercanidipine/enalapril.
    Hair PI; Scott LJ; Perry CM
    Drugs; 2007; 67(1):95-106; discussion 107-8. PubMed ID: 17209666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.
    Lacerda L; Faria AP; Fontana V; Moreno H; Sandrim V
    Arq Bras Cardiol; 2015 Aug; 105(2):168-75. PubMed ID: 26039662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of psychosomatic symptomatology in hypertensive patients treated with lercanidipine (LERCAPSICO study)].
    Abellán Alemán J; Martínez García JF; Merino Sánchez J; Gil Guillén V; Latorre Hernández J; Fernández Montero F; Navarro Lima A;
    An Med Interna; 2003 Jun; 20(6):287-91. PubMed ID: 12848598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial.
    Derosa G; Mugellini A; Querci F; Franzetti I; Pesce RM; D'Angelo A; Maffioli P
    Sci Rep; 2015 Aug; 5():12603. PubMed ID: 26243165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria.
    Pulido-Olmo H; García-Prieto CF; Álvarez-Llamas G; Barderas MG; Vivanco F; Aranguez I; Somoza B; Segura J; Kreutz R; Fernández-Alfonso MS; Ruilope LM; Ruiz-Hurtado G
    Clin Sci (Lond); 2016 Apr; 130(7):525-38. PubMed ID: 26733721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.